Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference
September 25 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, today announced that
Kenneth A. Berlin, President and Chief Executive Officer of
Advaxis, will present a corporate overview at the Cantor Fitzgerald
Global Healthcare Conference on Monday, October 1, 2018 at 9:30
a.m. Eastern time. The conference will be held October 1-3, 2018 at
the InterContinental New York Barclay Hotel.
Mr. Berlin’s presentation will be webcast live and available for
replay in the Investors section of the Company’s website at
www.ir.advaxis.com.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, personalized
neoantigen-directed immunotherapy, off-the-shelf, hotspot/cancer
antigens neoantigen-directed immunotherapy and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180925005182/en/
Investors:LHA Investor RelationsMiriam Weber Miller,
212-838-3777mmiller@lhai.comorAdvaxis, Inc.Ranya Dajani,
609-250-7559dajani@advaxis.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024
